Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Application of the revised International Prognostic Scoring System for myelodysplastic syndromes in Argentinean patients.

Belli CB, Bestach Y, Giunta M, Iastrebner M, Santos I, Pintos N, Arbelbide J, Basquiera AL, Bengió R, Larripa I.

Ann Hematol. 2014 Apr;93(4):705-7. doi: 10.1007/s00277-013-1848-4. Epub 2013 Jul 28. No abstract available.

PMID:
23892924
2.

Impacts of cytogenetic categories in the Revised International Prognostic Scoring System on the prognosis of primary myelodysplastic syndromes: results of a single-center study.

Qu S, Xu Z, Zhang Y, Qin T, Zhang T, Cui R, Xiao Z.

Leuk Lymphoma. 2012 May;53(5):940-6. doi: 10.3109/10428194.2011.634049. Epub 2011 Dec 6.

PMID:
22023524
3.

Partial and total monosomal karyotypes in myelodysplastic syndromes: comparative prognostic relevance among 421 patients.

Belli CB, Bengió R, Aranguren PN, Sakamoto F, Flores MG, Watman N, Nucifora E, Prates MV, Arbelbide J, Larripa I.

Am J Hematol. 2011 Jul;86(7):540-5. doi: 10.1002/ajh.22034. Epub 2011 Jun 14.

4.

The myelodysplastic syndrome-comorbidity index provides additional prognostic information on patients stratified according to the revised international prognostic scoring system.

Zipperer E, Tanha N, Strupp C, Kündgen A, Nachtkamp K, Neukirchen J, Hildebrandt B, Haas R, Gattermann N, Germing U.

Haematologica. 2014 Mar;99(3):e31-2. doi: 10.3324/haematol.2013.101055. Epub 2014 Jan 24. No abstract available.

5.

Outcome of patients with myelodysplastic syndromes: experience from a single institution in South Australia.

Hui CH, Horvath N, Lewis I, To LB, Szabo F.

Intern Med J. 2008 Nov;38(11):824-8. doi: 10.1111/j.1445-5994.2007.01582.x. Epub 2008 Feb 15.

PMID:
18284457
6.

Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.

Voso MT, Fenu S, Latagliata R, Buccisano F, Piciocchi A, Aloe-Spiriti MA, Breccia M, Criscuolo M, Andriani A, Mancini S, Niscola P, Naso V, Nobile C, Piccioni AL, D'Andrea M, D'Addosio A, Leone G, Venditti A.

J Clin Oncol. 2013 Jul 20;31(21):2671-7. doi: 10.1200/JCO.2012.48.0764. Epub 2013 Jun 24.

PMID:
23796988
7.

Improvement of the WHO classification-based prognostic scoring system (WPSS) by including age for Korean patients with the myelodysplastic syndrome.

Kim SH, Lee JH, Choi J, Kwon KA, Lee S, Oh SY, Kwon HC, Han JY, Kim HJ.

Leuk Res. 2010 Dec;34(12):1589-95. doi: 10.1016/j.leukres.2010.03.003. Epub 2010 Jul 14.

PMID:
20633929
8.

Detection of risk groups in myelodysplastic syndromes. A multicenter study.

Belli C, Acevedo S, Bengio R, Arrossagaray G, Watman N, Rossi N, García J, Flores G, Goldztein S, Larripa I.

Haematologica. 2002 Jan;87(1):9-16.

9.

Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system.

Aul C, Gattermann N, Heyll A, Germing U, Derigs G, Schneider W.

Leukemia. 1992 Jan;6(1):52-9.

PMID:
1736014
10.

Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS).

Germing U, Hildebrandt B, Pfeilstöcker M, Nösslinger T, Valent P, Fonatsch C, Lübbert M, Haase D, Steidl C, Krieger O, Stauder R, Giagounidis AA, Strupp C, Kündgen A, Mueller T, Haas R, Gattermann N, Aul C.

Leukemia. 2005 Dec;19(12):2223-31.

PMID:
16193087
11.

Classification and scoring systems in myelodysplastic syndromes: a retrospective analysis of 311 patients.

Navarro I, Ruiz MA, Cabello A, Collado R, Ferrer R, Hueso J, Martinez J, Miguel A, Orero MT, Pérez P, Nolasco A, Carbonell F.

Leuk Res. 2006 Aug;30(8):971-7. Epub 2006 Jan 19.

PMID:
16423393
12.

[The application of a new prognostic score system for 435 cases of primary myelodysplastic syndrome diagnosed with WHO classification].

Wang XQ; Sino-US Leukemia Cooperative Group of Shanghai..

Zhonghua Nei Ke Za Zhi. 2009 Aug;48(8):633-7. Chinese.

PMID:
19954053
13.

Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS).

Malcovati L, Della Porta MG, Strupp C, Ambaglio I, Kuendgen A, Nachtkamp K, Travaglino E, Invernizzi R, Pascutto C, Lazzarino M, Germing U, Cazzola M.

Haematologica. 2011 Oct;96(10):1433-40. doi: 10.3324/haematol.2011.044602. Epub 2011 Jun 9.

14.

Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS.

Park MJ, Kim HJ, Kim SH, Kim DH, Kim SJ, Jang JH, Kim K, Kim WS, Jung CW.

Eur J Haematol. 2008 Nov;81(5):364-73. doi: 10.1111/j.1600-0609.2008.01124.x. Epub 2008 Jul 10.

PMID:
18637029
15.

Serum ferritin is an independent prognostic factor in Chinese with myelodysplastic syndromes classified as IPSS Intermediate-1.

Li B, Xu Z, Gale RP, Qin T, Zhang Y, Xiao Z.

Acta Haematol. 2013;129(4):243-50. doi: 10.1159/000345428. Epub 2013 Jan 15.

PMID:
23328695
16.

Application of French prognostic score to patients with International Prognostic Scoring System intermediate-2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to predict overall survival and rate of response.

Breccia M, Loglisci G, Cannella L, Finsinger P, Mancini M, Serrao A, Santopietro M, Salaroli A, Alimena G.

Leuk Lymphoma. 2012 May;53(5):985-6. doi: 10.3109/10428194.2011.643408. Epub 2012 Jan 11. No abstract available.

PMID:
22112007
17.

[Myelodysplastic syndromes. A clinico-biological analysis of 27 cases].

Mereuţă A, Turtureanu-Hanganu E.

Rev Med Chir Soc Med Nat Iasi. 1990 Jan-Mar;94(1):67-73. Romanian.

PMID:
2075337
18.

Comparison of various criteria in predicting treatment response and prognosis of patients with myelodysplastic syndrome treated with azacitidine.

Kim DY, Lee JH, Lee JH, Lee KH, Kim YK, Ahn JS, Kim HJ, Kim I, Yoon SS, Park S, Bae SH, Bang SM, Lee HG, Shin HJ, Lee JH, Min YH, Won JH, Mun YC, Oh D; Korean Society of Hematology AML/MDS Working Party..

Ann Hematol. 2010 Jan;89(1):15-23. doi: 10.1007/s00277-009-0771-1. Epub 2009 Jun 19.

PMID:
19543727
19.

Levels of beta 2 microglobulin have a prognostic relevance for patients with myelodysplastic syndrome with regard to survival and the risk of transformation into acute myelogenous leukemia.

Neumann F, Gattermann N, Barthelmes HU, Haas R, Germing U.

Leuk Res. 2009 Feb;33(2):232-6. doi: 10.1016/j.leukres.2008.06.003. Epub 2008 Jul 18.

PMID:
18639338
20.

Supplemental Content

Support Center